Perrigo weakness creates buying opportunity, says Argus After Perrigo reported lower than expected Q3 EPS and reduced its guidance, Argus reports that the company's valuation are now in the lower portion of their historical levels. The firm cut its price target on the shares to $160 from $175 but it thinks the company has a number of positive catalysts and keeps a Buy rating.
Perrigo would be good acquisition for Teva, says RBC Capital RBC Capital views Perrigo (PRGO) as an attractive acquisition target and says in a note to investors that it thinks a takeover could be a good strategic fit with solid accretion for Teva (TEVA). Teva has interest in over-the-counter products and its growth rate would be boosted by the merger, RBC believes. The firm assumes a $200 per share value for Perrigo in its acquisition assumptions. Shares of the over-the-counter and generic pharmaceuticals company closed yesterday at $153.77.